1 results match your criteria: "Department of Metabolism and Physiology at the Moffitt Cancer Center[Affiliation]"
Article Synopsis
- Leptomeningeal disease (LMD) is a severe complication in late-stage melanoma, posing challenges for effective treatment due to its hidden location and unclear biology.
- Research identifies that the tumor microenvironment in LMD has low immune response but high stromal activity, promoting tumor survival and resistance to therapies.
- Targeting the stroma via SERPINA3 and its signaling pathways can resensitize melanoma cells to MAPK inhibitors, offering potential new strategies for treatment.